Home » Newsletters » BioWorld Science

BioWorld Science

June 5, 2019

View Archived Issues

'Perpetrators and targets' of CTLA-4 signaling

Healing bones during cancer remission

Final phase I data from ZUMA-3 for Kite's KTE-X19 in adult ALL

Allena Pharmaceuticals presents interim results from Study 206 of reloxaliase

FDA clears IND for ALLO-715

First patient dosed in B-SIMPLE phase III program of SB-206

iPPS shows promising safety and efficacy in phase IIa study in chronic RRV-induced arthralgia

First-in-human results presented for ABBV-621

Phase I study confirms Apexian Pharmaceuticals' APX-3330 mediates APE-1 activity

CDX-3379 plus cetuximab shows clinical activity in patients with HNSCC

Merck & Co. describes new PRMT5 inhibitors

Arcutis begins phase IIa trial of ARQ-151 in atopic dermatitis

Bayer and The Broad Institute synthesize Mcl-1 inhibitors

Jiangsu Chia Tai Tianqing Pharmaceutical Group, Medshine Discovery patent anti-HBV compounds

New slective estrogen receptor degraders identified at Anlin Pharmaceuticals

Teligene discloses Bruton tyrosine kinase and/or HER2 inhibitors

Safety results from CITN-12 study on pembrolizumab in patients with HIV and cancer

Cellenkos initiates phase I trial of CK-0801 for bone marrow failure syndromes

Oncolytic virus works in pediatric brain tumors

FDA approves Emgality for episodic cluster headache

FDA accepts Prevail's IND for phase I/II study of PR-001 for Parkinson's disease with GBA1 mutation

AZP-3404 restores glucose homeostasis in leptin-deficient obese mice

Anxiolytic effect for JNJ-61393215 seen in humans

Aslan reports final results from single-ascending-dose study of ASLAN-004

Hemogenyx reports in vivo data on CDX bispecific antibody for AML

Phase II trial of risuteganib for dry AMD meets primary endpoint

IND cleared for phase II trial of zilucoplan in immune-mediated necrotizing myopathy